Protagonist Therapeutics, Inc.
NASDAQ:PTGXBiotechnology
+$1.72 today
- Market cap
- $8.30B
- Beta
- 1.83
- P/E (TTM)
- -64.2
- EPS (TTM)
- -$1.76
Volume 0.43M
Average 0.72M
PTGX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Protagonist Therapeutics, Inc.NASDAQ: PTGX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $42.06M rose 13.6% year over year, behind the +21.8% change in trailing-twelve-month research & development. Sequentially, it fell 10.0% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.
Context
- Research & development amounted to 346.2% of revenue in FY2025, up 314.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.6% toward the trailing-twelve-month pace of +21.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 159.29M USD
- Year-over-year change
- +15.3%
- 4-year CAGR
- +6.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 159.29M | +15.3% |
| FY2024 | 2024-12-31 | 138.13M | +15.0% |
| FY2023 | 2023-12-31 | 120.16M | -4.8% |
| FY2022 | 2022-12-31 | 126.22M | +0.2% |
| FY2021 | 2021-12-31 | 126.01M | — |
Research & Development vs competitors
How PTGX compares with its peers on the latest reported figures
- PTGX's LTM Jun 2026 research & development of $175.16M is the 4th highest of the 7 companies compared; the peer median is $155.9M.
- Its year-over-year change of +21.8% is the 4th highest of 7, against a peer median of +19.4%.
- Research & development amounts to 62.1% of revenue for PTGX, versus a peer median of 482.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M | +16.2% | +41.8% | 6608.2% | |
| LTM Sep 2026 | $259.72M | +46.3% | +43.1% | 287.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $183.14M | +22.7% | +72.2% | — |
| LTM Jun 2026 | $175.16M | +21.8% | +8.1% | 62.1% | |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding PTGX) | $155.9M | +19.4% | +28.5% | 482.4% | |
Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.36M | 26.58M | 60M | 434.43M | 46.02M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Gross Profit | 27.36M | 26.58M | 60M | 434.43M | 44.79M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.3% |
| Research & Development | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
| Selling, General & Admin | 27.2M | 31.74M | 33.49M | 43.46M | 44.85M |
| Operating Expenses | 153.2M | 157.95M | 153.65M | 181.59M | 202.92M |
| Depreciation & Amortization | 2.78M | 3.37M | 3.31M | 2.96M | 1.28M |
| EBITDA | (122.78M) | (124.02M) | (75.64M) | 282.37M | (128.03M) |
| EBITDA Margin | -448.8% | -466.6% | -126.1% | 65.0% | -278.2% |
| Operating Income | (125.85M) | (131.37M) | (93.65M) | 252.84M | (158.13M) |
| Operating Margin | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% |
| Interest Income | 443K | 4.06M | 14.9M | 26.32M | 28.79M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 294K | 3.98M | 14.7M | 26.57M | 28.82M |
| Income Before Tax | (125.55M) | (127.39M) | (78.96M) | 279.41M | (129.31M) |
| Pre-Tax Margin | -458.9% | -479.3% | -131.6% | 64.3% | -281.0% |
| Income Tax Expense | 0 | 0 | 0 | 4.22M | 838K |
| Net Income | (125.55M) | (127.39M) | (78.96M) | 275.19M | (130.15M) |
| Net Margin | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% |
| EPS (Basic) | (2.65) | (2.52) | (1.39) | 4.47 | (2.05) |
| EPS (Diluted) | (2.65) | (2.52) | (1.39) | 4.23 | (2.05) |
| Weighted Avg Shares | 46.32M | 49.04M | 56.76M | 61.57M | 63.57M |
| Weighted Avg Shares (Diluted) | 46.32M | 49.04M | 56.76M | 65.08M | 63.57M |
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Intrinsic Alpha fair value
Locked
Current Price
$127.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.